EYLEA Drug Profile

Summary for Tradename: EYLEA

High Confidence Patents:	56
Applicants:	1
BLAs:	2

Pharmacology for EYLEA

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EYLEA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EYLEA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2037-03-28	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2036-03-10	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2038-10-12	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2038-10-12	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2038-08-06	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2039-04-29	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2040-08-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for EYLEA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2037-12-21	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2035-11-23	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2036-11-15	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2035-03-17	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2038-05-25	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2036-06-13	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387		2036-08-10	Patent claims search

International Patents for EYLEA

Country	Patent Number	Estimated Expiration
China	118494967
Brazil	112021025769
Australia	2020323937
Israel	296864
Japan	2019150037
Singapore	10201707153U
Taiwan	I330197

Supplementary Protection Certificates for EYLEA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
20/2013	Austria		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001 UND 002 20121122
CR 2013 00020	Denmark		PRODUCT NAME: AFLIBERCEPT; REG. NO/DATE: EU/1/797/001-002 20121122
C300588	Netherlands		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
SPC/GB13/028	United Kingdom		PRODUCT NAME: AFLIBERCEPT; REGISTERED: UK EU/1/12/797/001 20121122; UK EU/1/12/797/002 20121122
C01183353/01	Switzerland		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: SWISSMEDIC 62397 29.10.2012
2013/016	Ireland		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122
92195	Luxembourg		PRODUCT NAME: AFLIBERCEPT (EYLEA - ZALTRAP)

EYLEA (Aflibercept) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

EYLEA (aflibercept), developed by Regeneron Pharmaceuticals, is a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases. Its market performance is shaped by patent exclusivity, clinical efficacy, therapeutic alternatives, and regulatory approvals.

What is EYLEA's Market Position and Competitive Landscape?

EYLEA has maintained a dominant position in the treatment of wet AMD and DME since its U.S. Food and Drug Administration (FDA) approval in 2011. Its mechanism of action, targeting multiple VEGF isoforms, provides robust efficacy, leading to sustained visual acuity gains for patients.

The competitive landscape is evolving, primarily driven by biosimilar entrants and the development of new therapeutic modalities.

Key Competitors

• Ranibizumab (Lucentis): Developed by Genentech/Roche, ranibizumab was the first VEGF inhibitor approved for wet AMD. While EYLEA demonstrated comparable or superior efficacy in some head-to-head trials, Lucentis remains a significant competitor.
• Bevacizumab (Avastin): While not FDA-approved for ocular use, bevacizumab is widely used off-label due to its lower cost. This off-label use presents a persistent cost-based competitive pressure.
• Faricimab (Vabysmo): Developed by Genentech/Roche, faricimab is a bispecific antibody that targets both VEGF-A and angiopoietin-2 (Ang-2). It received FDA approval in 2022 for wet AMD and DME and offers a potentially longer duration of action, positioning it as a direct competitor.
• Brolucizumab (Beovu): Developed by Novartis, brolucizumab is a single-chain antibody fragment targeting VEGF-A. Approved in 2019, its market penetration has been impacted by concerns regarding intraocular inflammation and vasculitis.
• Biosimilars: As EYLEA's core patents approach expiration, biosimilar versions are emerging. Biosimilar aflibercept has been approved in markets outside the U.S., and anticipated U.S. launches are expected to increase price competition. Key biosimilar developers include Samsung Bioepis and Biogen.

What are EYLEA's Intellectual Property and Patent Expirations?

EYLEA's market exclusivity has been underpinned by a robust patent portfolio. However, significant patents are set to expire, paving the way for biosimilar competition.

Key Patents and Expiration Timeline

• U.S. Patent No. 8,785,422 (Formulation Patent): This patent, covering EYLEA's formulation, was a key point of contention in litigation. Its expiration significantly opened the door for biosimilar development. It expired in September 2023 [1].
• U.S. Patent No. 7,074,433 (Composition of Matter Patent): The primary patent covering the aflibercept molecule. While initially set to expire earlier, extensions and subsequent litigation have influenced its effective market exclusivity. This patent expired in November 2023 [1].
• Other Patents: Regeneron holds numerous secondary patents related to manufacturing processes, methods of use, and specific indications. These are subject to ongoing legal challenges and can influence the timing and scope of biosimilar market entry.

The expiration of the primary composition of matter and formulation patents signifies the end of EYLEA's core market exclusivity in the United States.

What is EYLEA's Revenue Generation and Financial Performance?

EYLEA has been a cornerstone of Regeneron's revenue, generating billions of dollars annually. Its financial trajectory reflects strong initial adoption, sustained demand, and the impact of market exclusivity.

Historical Revenue Performance

Year	Net Sales (Billions USD)
2020	$9.57
2021	$10.23
2022	$11.18
2023	$11.15 (Approximate)

Source: Regeneron Pharmaceuticals Annual Reports and Investor Filings.

EYLEA's sales peaked in 2022. The slight decline or plateau in 2023 indicates the early stages of market maturation and the anticipated impact of upcoming biosimilar competition, alongside the launch of new therapeutic options like Vabysmo.

Impact of Biosimilars on Future Revenue

The introduction of biosimilar aflibercept is projected to significantly impact EYLEA's revenue. Based on experiences with other biologics, biosimilar entry typically leads to substantial price erosion. Regeneron has implemented strategies, including the development of EYLEA 4 mL (a higher volume, lower concentration formulation intended to be more cost-effective for high-treatment-burden patients) and EYLEA HD (a high-dose formulation intended for less frequent dosing), to mitigate these effects. EYLEA HD received FDA approval in August 2023 and was launched in September 2023 [2]. This new formulation aims to compete on a dosing regimen basis and potentially extend market life.

What are the Key Regulatory Milestones and Approvals?

EYLEA's approval history spans multiple indications, demonstrating its broad therapeutic utility in retinal diseases.

Major Regulatory Approvals (U.S.)

• October 2011: FDA approval for the treatment of wet age-related macular degeneration (AMD).
• June 2012: FDA approval for the treatment of macular edema following retinal vein occlusion (RVO).
• August 2014: FDA approval for the treatment of diabetic macular edema (DME).
• November 2016: FDA approval for the treatment of neovascular glaucoma (NVG).
• August 2023: FDA approval for EYLEA HD (aflibercept 8 mg) for wet AMD, DME, and RVO.

These approvals expanded EYLEA's addressable market and solidified its therapeutic role across various ophthalmic conditions.

What is the Global Market Penetration and Pricing Strategy?

EYLEA is marketed globally by Regeneron and its partner Bayer AG (outside the U.S., except for Japan). Pricing strategies have evolved to reflect market dynamics, competition, and the value proposition of its efficacy.

Global Market Presence

• United States: Marketed by Regeneron.
• Europe, Japan, and other countries: Marketed by Bayer.
• China: Marketed by Sanofi through a licensing agreement.

Pricing for EYLEA has historically been at a premium, reflecting its innovative nature and clinical benefits. With the advent of biosimilars and new therapeutic options, pricing strategies are under pressure. The introduction of EYLEA HD, with its longer dosing interval, is a strategic move to offer a value proposition beyond just price, focusing on patient convenience and potentially reduced overall treatment burden.

The average wholesale price (AWP) for EYLEA injections has historically been in the range of $1,800 to $2,000 per dose, varying slightly by formulation and region. Biosimilar pricing is anticipated to be 20-40% lower than branded EYLEA, depending on market penetration and payer negotiations.

What are the Future Market Outlook and Growth Drivers?

The future market for EYLEA and its biosimilars will be influenced by several factors.

Key Outlook Factors

• Biosimilar Competition: The primary driver of market change. Multiple biosimilar aflibercept products are expected to launch in the U.S. in 2024 [3]. This will lead to significant price erosion and a shift in market share.
• EYLEA HD Performance: The success of EYLEA HD in capturing market share from its predecessor and competing with other long-acting agents will be crucial for Regeneron's continued revenue generation. Its approval for less frequent dosing (every 8 to 16 weeks) offers a competitive advantage over older formulations requiring monthly injections.
• Emerging Therapies: Continued innovation in retinal disease treatment, including gene therapy and novel small molecules, could introduce new competitive pressures.
• Real-World Evidence: Accumulating real-world data on the efficacy and safety of EYLEA HD and competing agents will influence prescribing patterns.
• Payer Policies: Payer coverage decisions and formulary placement for biosimilars and EYLEA HD will significantly impact market access and uptake.

The market for anti-VEGF therapy is expected to grow due to an aging global population and increasing prevalence of retinal diseases. However, the growth will likely be driven by volume rather than price, with increased utilization of biosimilars and potentially EYLEA HD.

Projected Market Shift

The market share of branded EYLEA is projected to decline rapidly following biosimilar launches. Regeneron aims to offset this decline through the adoption of EYLEA HD, which is positioned to compete on efficacy and dosing frequency rather than solely on price. The overall anti-VEGF market, however, is expected to expand, absorbing both biosimilar and novel therapies.

Key Takeaways

• EYLEA has been a blockbuster drug, generating over $10 billion annually.
• Core patent expirations in late 2023 have opened the U.S. market to biosimilar competition.
• Multiple aflibercept biosimilars are expected to launch in 2024, leading to significant price erosion.
• Regeneron's EYLEA HD (aflibercept 8 mg), approved in August 2023, is its key strategy to retain market share through extended dosing intervals.
• The competitive landscape includes established drugs like Lucentis and emerging therapies such as Vabysmo.
• Global revenue generation is shared between Regeneron (U.S.) and Bayer (ex-U.S.).

FAQs

1. When did EYLEA (aflibercept) receive its initial FDA approval? EYLEA received its initial FDA approval for the treatment of wet age-related macular degeneration (AMD) in October 2011.

2. What is the primary mechanism of action for EYLEA? EYLEA is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), blocking their interaction with VEGF receptors, thereby inhibiting neovascularization and reducing vascular permeability.

3. What are the main indications for EYLEA? The primary indications for EYLEA include wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It is also approved for neovascular glaucoma (NVG).

4. What is EYLEA HD, and how does it differ from the original EYLEA formulation? EYLEA HD is a high-dose formulation of aflibercept (8 mg) approved in August 2023. It is designed for less frequent intravitreal injections compared to the original EYLEA formulation (2 mg), offering dosing every 8 to 16 weeks for certain indications, versus every 4 to 8 weeks for the original.

5. Which companies are involved in the U.S. market for EYLEA and its biosimilars? In the U.S., Regeneron Pharmaceuticals originally developed and markets EYLEA. Biosimilar versions are being developed and are expected to be marketed by companies such as Samsung Bioepis and Biogen, among others.

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from USPTO Patent Public Search [2] Regeneron Pharmaceuticals. (2023, August 21). FDA Approves EYLEA® HD (aflibercept) Injection for Wet Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. [Press Release]. [3] Generic & Biosimilar Drug Report. (2023, December 15). FDA Approves First Biosimilar for Regeneron’s Eylea. Retrieved from Generic & Biosimilar Drug Report